Hematopoiesis News 7.26 July 5, 2016 | |
| |
TOP STORYScientists depleted hematopoietic stem and progenitor cells in adult mice in situ and found that long term repopulating hematopoietic stem cells recovered from initially very low levels to below 10% of normal numbers but not more, while progenitor cells substantially recovered shortly after depletion. [Blood] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)A Single Cell Resolution Map of Mouse Hematopoietic Stem and Progenitor Cell Differentiation Investigators used single cell RNA-Seq to profile over 1,600 single hematopoietic stem and progenitor cells, where deep sequencing has enabled detection of an average of 6,558 protein-coding genes per cell. [Blood] Abstract Investigators sought to comprehensively examine formaldehyde hematoxicity in vivo in mouse peripheral blood, bone marrow, spleen and myeloid progenitors. [Arch Toxicol] Abstract Scientists demonstrated that activation of HOXB4 does increase the production of hematopoietic progenitor cells from human pluripotent stem cells as determined by colony-forming unit culture activity and the presence of CD43+CD34+ progenitors. [Stem Cells Transl Med] Abstract | Full Article ASXL1 Plays an Important Role in Erythropoiesis Scientists showed that chronic myelomonocytic leukemia (CMML) patients with ASXL1 mutations exhibited more severe anemia with a significantly increased proportion of bone marrow early stage erythroblasts and reduced enucleated erythrocytes compared to CMML patients with WT ASXL1. [Sci Rep] Full Article Researchers compared the therapeutic effects of single umbilical cord blood transplantation and unmanipulated haplo-hematopoietic stem cell transplantation in high-risk acute lymphoblastic leukemia children. [Int J Cancer] Abstract Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia miRNA profiles were globally altered in acute lymphoblastic leukemia cells following exposure to primary human bone marrow niche cells including bone marrow stromal cells and primary human osteoblasts. [Mol Cancer Res] Abstract The authors also attempted to interrogate similarities between aging human and murine hematopoiesis. Coupled to the transition from human cord blood to young and aged bone marrow, they observed a gradual increase in frequency of candidate hematopoietic stem cells. [PLoS One] Full Article Low Doses of Oxygen Ion Irradiation Cause Acute Damage to Hematopoietic Cells in Mice Researchers investigated the acute effects of low doses of 16oxygen (16O) irradiation on the hematopoietic system. They exposed C57BL/6J mice to 0.1, 0.25 and 1.0 Gy whole body 16O irradiation and examined the effects on peripheral blood cells, and bone marrow hematopoietic stem cells and hematopoietic progenitor cells at two weeks after the exposure. [PLoS One] Full Article CLINICAL RESEARCHIncreased Hematopoietic Activity in Patients with Atherosclerosis Considering the chronic low-grade inflammatory state in atherosclerosis, the authors hypothesized that hematopoietic hyperactivity is a persistent feature in cardiovascular disease. They aimed to assess the activity of hematopoietic organs and hematopoietic stem and progenitor cells in humans. [Eur Heart J] Abstract | |
| |
REVIEWSThe pre-emptive use of plerixafor added to mobilization with chemotherapy plus granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone has gained more popularity. This approach may be more cost-effective than the routine use of this drug. [Expert Rev Hematol] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
| |
INDUSTRY NEWSKiadis Pharma N.V. announced that its lead product, ATIR101™, has been granted an expansion to its existing Orphan Drug Designation by the European Medicines Agency to include treatment in a hematopoietic stem cell transplantation. [Kiadis Pharma N.V.] Press Release Actinium Pharmaceuticals Initiates Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc. announced that the pivotal Phase III clinical trial for Iomab-B has been initiated. Iomab-B upon approval, is intended to be an induction and conditioning agent used to prepare patients with relapsed or refractory AML who are over the age of 55 for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. [Actinium Pharmaceuticals, Inc.] Press Release -Bristol-Myers Squibb Company and PsiOxus Therapeutics, Ltd. announced an exclusive clinical collaboration agreement to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev, asystemically administered oncolytic adenovirus therapeutic, in combination with Bristol-Myers Squibb’s Immuno-Oncology agent Opdivo to treat a range of tumor types in late-stage cancer patients. [PsiOxus Therapeutics, Ltd.] Press Release | |
From our sponsor: Want to learn more about ALDH in breast cancer treatment response? Listen to the podcast.
| |
EVENTSNEW Nordic Life Science Days 2016 Visit our events page to see a complete list of events in the hematopoiesis community.
| |
JOB OPPORTUNITIESScientist – Hematology (STEMCELL Technologies Inc.) Technical Sales Representative (STEMCELL Technologies Inc.) Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University) Postdoctoral Fellow – Characterizing and Targeting Cancer Stem Cells (City of Hope) Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Novartis) Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London) Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University) Postdoctoral Fellow – Leukemia Lymphoma (Emory University) Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center) Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|